Protective effects of green tea on olanzapine-induced-metabolic syndrome in rats

Biomedicine and Pharmacotherapy

Volumn 92, Issue , 2017, Pages 726-731

  Razavi, Bibi Marjan ^a   Lookian, Fariba ^b   Hosseinzadeh, Hossein ^c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Camellia sinensis; Green tea; Leptin; Metabolic syndrome; Olanzapine; Weight gain

Indexed keywords

GALLIC ACID; GLUCOSE; LEPTIN; LIPID; OLANZAPINE; SINECATECHINS; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; POLYPHENOL; PROTECTIVE AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG SCREENING; DYSLIPIDEMIA; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERLEPTINEMIA; HYPERTENSION; LIPID BLOOD LEVEL; LOCOMOTION; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ANIMAL; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CHEMICALLY INDUCED; CHEMISTRY; DRINKING; DRUG EFFECTS; FEEDING BEHAVIOR; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; SYSTOLE; TEA; WISTAR RAT;

ANIMALS; BENZODIAZEPINES; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DRINKING; FEEDING BEHAVIOR; LEPTIN; LIPIDS; MALE; METABOLIC SYNDROME; MOTOR ACTIVITY; POLYPHENOLS; PROTECTIVE AGENTS; RATS, WISTAR; SYSTOLE; TEA; TRIGLYCERIDES;

EID: 85020011922     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2017.05.113     Document Type: Article

References (53)

1. Jarskog, L., Miyamoto, S., Lieberman, J., Schizophrenia: new pathological insights and therapies. Annu. Rev. Med. 58 (2007), 49–61.
2. Baptista, T., Kin, N., Beaulieu, S., de Baptista, E., Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35 (2002), 205–219.
3. Pramyothin, P., Khaodhiar, L., Metabolic syndrome with the atypical antipsychotics. Curr. Opin. Endocrinol. Diab. Obes. 17 (2010), 460–466.
4. Riordan, H., Antonini, P., Murphy, M., Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications. Am. Health Drug Benefits, 2011, 292–302.
5. Kirk, S., Glazebrook, J., Grayson, B., Neill, J., Reynolds, G., Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology (Berl.) 207 (2009), 119–125.
6. Gracious, B.L., Meyer, A.E., Psychotropic-induced weight gain and potential pharmacologic treatment strategies. Psychiatry 2 (2005), 36–42.
7. Gunes, A., Melkersson, K., Scordo, M., Dahl, M., Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J. Clin. Psychopharmacol. 29 (2009), 65–68.
8. Evers, S.S., Calcagnoli, F., Dijk, V., Scheurink, A.J.W., Olanzapine causes hypothermia inactivity, a deranged feeding pattern and weight gain in female Wistar rats. Pharmacol. Biochem. Behav. 97 (2010), 163–169.
9. Weston-Greena, K., Huanga, X., Denga, C., Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats. Behav. Brain Res. 217 (2011), 337–346.
10. Hara, Y., Green Tea: Health Benefits and Applications. 2001, Marcel Dekker Inc., New York.
11. Lin, J., Lin, C., Liang, Y., Lin-Shiau, S., Juan, I., Survey of catechins gallic acid, and methylxanthines in green, oolong, pu-erh, and black teas. J. Agric. Food Chem. 46 (1998), 3635–3642.
12. Esmaeelpanah, E., Rahmatkhah, A., Poormahmood, N., Razavi, B.M., Hasani, F.V., Hosseinzadeh, H., Protective effect of green tea aqueous extract on acrylamide induced neurotoxicity. Jundishapur J. Nat. Pharm. Prod. 10 (2015), 101–105.
13. Wolfram, S., Wang, Y., Thielecke, F., Anti-obesity effects of green tea: from bedside to bench. Mol. Nutr. Food Res. 50 (2006), 176–187.
14. Rameshrad, M., Razavi, B.M., Hosseinzadeh, H., Protective effects of green tea and its main constituents against natural and chemical toxins: a comprehensive review. Food Chem. Toxicol. 100 (2017), 115–137.
15. Sae-tan, S., Grove, K., Lambert, J., Weight control and prevention of metabolic syndrome by green tea. Pharmacol. Res. 64 (2011), 146–154.
16. Werneke, U., Taylor, D., Sanders, T., Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int. Clin. Psychopharmacol. 17 (2002), 145–160.
17. Akaberi, M., Hosseinzadeh, H., Grapes (Vitis vinifera) as a potential candidate for the therapy of the metabolic syndrome. Phytother. Res. 30:30 (2016), 540–556.
18. Razavi, B.M., Hosseinzadeh, H., A review of the effects of Nigella sativa L. and its constituent thymoquinone, in metabolic syndrome. J. Endocrinol. Invest. 37 (2014), 1031–1040.
19. Hosseini, A., Hosseinzadeh, H., A review on the effects of Allium sativum (Garlic) in metabolic syndrome. J. Endocrinol. Invest. 38 (2015), 1147–1157.
20. Hassani, F.V., Shirani, K., Hosseinzadeh, H., Rosemary (Rosmarinus officinalis) as a potential therapeutic plant in metabolic syndrome: a review, Naunyn Schmiedebergs. Arch. Pharmacol. 389 (2016), 931–949.
21. Razavi, B.M., Hosseinzadeh, H., Saffron: a promising natural medicine in the treatment of metabolic syndrome. J. Sci. Food Agric. 97 (2017), 1679–1685.
22. Tabeshpour, J., Razavi, B.M., Hosseinzadeh, H., Effects of avocado (Persea americana) on metabolic syndrome: a comprehensive systematic review. Phytother. Res., 2017, 10.1002/ptr.5805 (in press).
23. Mollazadeh, H., Hosseinzadeh, H., Cinnamon effects on metabolic syndrome: a review based on its mechanisms. Iran. J. Basic Med. Sci. 19 (2016), 1258–1270.
24. Hosseinzadeh, H., Nassiri-Asl, M., Review of the protective effects of rutin on the metabolic function as an important dietary flavonoid. J. Endocrinol. Invest. 37 (2014), 783–788.
25. Bajerska, J., Wozniewicz, M., Jeszka, J., Drzymala-Czyz, S., Walkowiak, J., Green tea aqueous extract reduces visceral fat and decreases protein availability in rats fed with a high-fat diet. Nutr. Res. 31 (2011), 157–164.
26. Armoskaite, V., Ramanauskiene, K., Maruska, A., Razukas, A., Dagilyte, A., Baranauskas, A., The analysis of quality and antioxidant activity of green tea extracts. J. Med. Plants Res. 5 (2011), 811–816.
27. Choi, S., DiSilvio, B., Unangst, J., Fernstrom, J., Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci. 81 (2007), 1024–1030.
28. Patil, B., Kulkarni, N., Unger, B., Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain. Eur. J. Pharmacol. 551 (2006), 112–115.
29. Kim, H., Park, M., Lee, S.K., Jeong, J., Namkoong, K., Cho, H.-S., Phosphorylation of hypothalamic AMPK on serine485/491 related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine. Psychopharmacology (Berl.) 231 (2014), 4059–4069.
30. Arjona, A., Zhang, S., Adamsona, B., Wurtman, R., An animal model of antipsychotic-induced weight gain. Behav. Brain Res. 152 (2004), 121–127.
31. Ratzoni, G., Gothelf, D., Brand-Gothelf, A., Reidman, J., Kikinzon, L., Gal, G., Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J. Am. Acad. Child Adolesc. Psychiatry 41 (2002), 337–343.
32. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., Barbui, C., Engel, R.R., Geddes, J.R., Kissling, W., Stapf, M.P., Lässig, B., Salanti, G., Davis, J.M., Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments. Meta-analysis. Lancet 382 (2013), 951–962.
33. Albaugh, V., Henry, C., Bello, N., Hajnal, A., Lynch, S., Halle, B., Lynch, C.J., Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity 14 (2006), 36–51.
34. Potvin, S., Zhornitsky, S., Stip, E., Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. Can. J. Psychiatry 60 (2015), S26–S34.
35. Cao, H., Adipocytokines in obesity and metabolic disease. J. Endocrinol. 220 (2014), T47–59.
36. McIntyre, R.S., Mancini, D.A., Basile, V.S., Srinivasan, J., Kennedy, S.H., Antipsychotic-induced weight gain: bipolar disorder and leptin. J. Clin. Psychopharmacol. 23 (2003), 323–327.
37. Ananth, J., Venkatesh, R., Burgoyne, K., Gadasalli, R., Binford, R., Gunatilake, S., Atypical antipsychotic induced weight gain: pathophysiology and management. Ann. Clin. Psychiatry 16 (2004), 75–85.
38. Sejima, E., Yamauchi, A., Nishioku, T., Koga, M., Nakagama, K., Dohgu, S., Futagami, K., Kataoka, Y., A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats. Cell. Mol. Neurobiol. 31 (2011), 985–989.
39. Phung, O.J., Baker, W.L., Matthews, L.J., Lanosa, M., Thorne, A., Coleman, C.I., Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis. Am. J. Clin. Nutr. 91 (2010), 73–81.
40. Bose, M., Lambert, J., Ju, J., Reuhl, K., Shapses, S., Yang, C., The major green tea polyphenol (−)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J. Nutr. Biochem. 138 (2008), 1677–1683.
41. Sayama, K., Lin, S., Zheng, G., Oguni, I., Effects of green tea on growth, food utilization and lipid metabolism in mice. In Vivo 14 (2000), 481–484.
42. Michna, L., Lu, Y., Lou, Y., Wagner, G., Conney, A., Stimulatory effect of oral administration of green tea and caffeine on locomotor activity in SKH-1 mice. Life Sci. 73 (2003), 1383–1392.
43. Chang, S., Lu, M., Metabolic and cardiovascular adverse effects associated with treatment with antipsychotic drugs. J. Exp. Clin. Med., 4, 2012, 103e7.
44. Galassi, A., Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am. J. Med. 119 (2006), 812–819.
45. Buchholz, S., Morrow, A.F., Coleman, P.L., Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms. Int. Med. J. 38 (2008), 602–606.
46. Iso, H., Date, C., Wakai, K., Fukui, M., Tamakoshi, A., The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Ann. Intern. Med. 144 (2006), 554–562.
47. Wolfram, S., Raederstorff, D., Preller, M., Wang, Y., Teixeira, S.R., Riegger, C., Epigallocatechin gallate supplementation alleviates diabetes in rodents. J. Nutr. Biochem. 136 (2006), 2512–2518.
48. Waltner-Law, M.E., Wang, X.L., Law, B.K., Hall, R.K., Nawano, M., Granner, D.K., Epigallocatechin gallate aconstituent of green tea, represses hepatic glucose production. J. Biol. Chem. 277 (2002), 34933–34940.
49. Anderson, R., Polansky, M., Tea enhances insulin activity. Agric. Food Chem. J. 50 (2002), 7182–7186.
50. Tsuneki, H., Ishizuka, M., Terasawa, M., Wu, J., Sasaoka, T., Kimura, I., Effect of green tea on blood glucose levels and serum proteomic patterns in diabetic (db/db) mice and on glucose metabolism in healthy humans. BMC Pharmacol. 4 (2004), 18–21.
51. Han, M., Epigallocatechin gallate, a constituent of green tea, suppresses cytokine-induced pancreatic beta-cell damage. Exp. Mol. Med. 35 (2003), 136–139.
52. Kobayashi, Y., Suzuki, M., Satsu, H., Arai, S., Hara, Y., Suzuki, K., Miyamoto, Y., Shimizu, M., Green tea polyphenols inhibit the sodium-dependent glucose transporter of intestinal epithelial cells by a competitive mechanism. J. Agric. Food Chem. 48 (2000), 5618–5623.
53. Bogdanskia, P., Suliburskab, J., Szulinskaa, M., Stepiena, M., Pupek-Musialika, D., Jablecka, A., Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients. Nutr. Res. 32 (2012), 421–427.